Scarica l'app Stockscreener
18.23
5.89%
-1.14
Dopo l'orario di chiusura:
18.23
Precedente Chiudi:
$19.37
Aprire:
$19.22
Volume 24 ore:
157.90K
Relative Volume:
0.82
Capitalizzazione di mercato:
$975.86M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-25.33
EPS:
-0.7198
Flusso di cassa netto:
-
1 W Prestazione:
-16.07%
1M Prestazione:
+10.89%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$17.92
$19.90
Intervallo di 1 settimana:
$17.92
$22.07
Portata 52W:
$14.85
$22.98
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Nome
Seaport Therapeutics Inc
Settore
Industria
Telefono
617-807-4062
Indirizzo
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
18.23 | 1.04B | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seaport Therapeutics Inc Borsa (SPTX) Ultime notizie
Price to earnings forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
SPTX Forecast — Price Target — Prediction for 2027 - TradingView
Seaport Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPTX) - TradingView
SPTX Price Today: Seaport Therapeutics, Inc. Stock Price, Quote & Chart - mexc.co
Price to book forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Enterprise value to EBIT forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Insider Stock Purchases: June 24, 2026 - Moomoo
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
PureTech-founded Seaport Therapeutics advances anxiety drug after positive Phase 1 data - grafa.com
J.P. Morgan Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
PureTech-founded Seaport reports positive GlyphAgo phase 1 data - marketscreener.com
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target By Investing.com - Investing.com Nigeria
New oral anxiety drug aims to cut liver tests after early trial - Stock Titan
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target - Investing.com India
PureTech Highlights Seaport Progress as GlyphAgo Advances Following Positive Phase 1 Anxiety Trial Results (PRTC) - Yahoo Finance UK
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgotm in Healthy Volunteers - Lelezard
Seaport Therapeutics reports positive phase 1 data for GlyphAgo By Investing.com - Investing.com Nigeria
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Yahoo Finance
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Positive Trial Results for Seaport Therapeutics (SPTX) in Anxiet - GuruFocus
Seaport Therapeutics reports Q1 2026 financials and pipeline progress - grafa.com
Seaport Pops on Q1 Numbers - Baystreet.ca
Seaport Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Seaport Therapeutics Reports Strong Q1 2026 Results, Advances Neuropsychiatric Drug Pipeline, and Raises $260M in IPO - Minichart
Seaport Therapeutics reports phase 1 data for anxiety drug By Investing.com - Investing.com South Africa
Seaport Therapeutics 1Q 2026: Net loss $(25.4M), EPS $(10.34) — 10-Q Summary - TradingView
Seaport Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
SPTX: Q1 2026 net loss rose to $25.4M; cash and investments total $212.6M post-IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, vs. FactSet Est of $10.64 Loss - marketscreener.com
Seaport Therapeutics reports phase 1 data for anxiety drug - Investing.com
SPTX: Clinical progress and $260M IPO extend cash runway into 2029 amid increased R&D investment - TradingView
Seaport Therapeutics reports Q1 2026 net loss of $25.4M, cash $212.6M before $260M IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, Vs. FactSet Est of $10.64 Loss - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers - TradingView
Press Release: Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - The Joplin Globe
Seaport Therapeutics Inc Azioni (SPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Seaport Therapeutics Inc Azioni (SPTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
May 04 '26 |
Buy |
18.00 |
1,100,000 |
19,800,000 |
6,294,951 |
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):